Document Detail


Prophylactic effect of UFT on the recurrence of bladder cancer
MedLine Citation:
PMID:  2116083     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To evaluate the effect of UFT, a mixture of ftorafur and uracil in a ratio of 1:4, in preventing postoperative recurrence of bladder cancer, we performed a randomized controlled study with a non-medication group as control. UFT was given orally 400 mg a day for 6 months. Of 111 patients, 56 were given UFT and 55 were followed up without any medication. The non-recurrence rate in the group treated with UFT was 62.8% after 1 year and 36.3% after 2 years of follow up, and that of the control group was 45.7% and 39.5%, respectively. The rate of non-recurrence in the UFT group was significantly higher (p less than 0.05) than that of the control group during the period of follow up for 2 years. The incidence of side effects was 6.8% in UFT patients. These results indicate the clinical usefulness of prophylactic administration of UFT for bladder cancer patients.
Authors:
K Naito; H Hisazumi; A Saka; T Nakamura; S Kanda; I Mikawa; S Ejiri; T Miyagi; T Katsumi; K Kitagawa
Publication Detail:
Type:  Clinical Trial; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Hinyokika kiyo. Acta urologica Japonica     Volume:  36     ISSN:  0018-1994     ISO Abbreviation:  Hinyokika Kiyo     Publication Date:  1990 Apr 
Date Detail:
Created Date:  1990-09-05     Completed Date:  1990-09-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0421145     Medline TA:  Hinyokika Kiyo     Country:  JAPAN    
Other Details:
Languages:  jpn     Pagination:  487-94     Citation Subset:  IM    
Affiliation:
Department of Urology, School of Medicine, Kanazawa University.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Transitional Cell / drug therapy,  prevention & control*,  surgery
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Japan
Male
Middle Aged
Multicenter Studies as Topic
Neoplasm Recurrence, Local / prevention & control*
Prospective Studies
Randomized Controlled Trials as Topic
Tegafur / administration & dosage
Uracil / administration & dosage
Urinary Bladder Neoplasms / drug therapy,  prevention & control*,  surgery
Chemical
Reg. No./Substance:
17902-23-7/Tegafur; 66-22-8/Uracil; 74578-38-4/1-UFT protocol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravesical instillation chemotherapy of anticancer agents including cylocide: studies of prophylac...
Next Document:  Phase II trial of carboplatin and tegafur (Ftorafur) as induction therapy in squamous-cell carcinoma...